214 related articles for article (PubMed ID: 20531394)
1. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.
Hadaczek P; Eberling JL; Pivirotto P; Bringas J; Forsayeth J; Bankiewicz KS
Mol Ther; 2010 Aug; 18(8):1458-61. PubMed ID: 20531394
[TBL] [Abstract][Full Text] [Related]
2. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
Ciesielska A; Sharma N; Beyer J; Forsayeth J; Bankiewicz K
PLoS One; 2015; 10(4):e0122708. PubMed ID: 25860990
[TBL] [Abstract][Full Text] [Related]
3. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.
Bankiewicz KS; Forsayeth J; Eberling JL; Sanchez-Pernaute R; Pivirotto P; Bringas J; Herscovitch P; Carson RE; Eckelman W; Reutter B; Cunningham J
Mol Ther; 2006 Oct; 14(4):564-70. PubMed ID: 16829205
[TBL] [Abstract][Full Text] [Related]
5. Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys.
Daadi MM; Pivirotto P; Bringas J; Cunningham J; Forsayeth J; Eberling J; Bankiewicz KS
Neuroreport; 2006 Feb; 17(2):201-4. PubMed ID: 16407771
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Bankiewicz KS; Eberling JL; Kohutnicka M; Jagust W; Pivirotto P; Bringas J; Cunningham J; Budinger TF; Harvey-White J
Exp Neurol; 2000 Jul; 164(1):2-14. PubMed ID: 10877910
[TBL] [Abstract][Full Text] [Related]
7. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.
Forsayeth JR; Eberling JL; Sanftner LM; Zhen Z; Pivirotto P; Bringas J; Cunningham J; Bankiewicz KS
Mol Ther; 2006 Oct; 14(4):571-7. PubMed ID: 16781894
[TBL] [Abstract][Full Text] [Related]
8. Dimerizer regulation of AADC expression and behavioral response in AAV-transduced 6-OHDA lesioned rats.
Sanftner LM; Rivera VM; Suzuki BM; Feng L; Berk L; Zhou S; Forsayeth JR; Clackson T; Cunningham J
Mol Ther; 2006 Jan; 13(1):167-74. PubMed ID: 16126007
[TBL] [Abstract][Full Text] [Related]
9. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
Sánchez-Pernaute R; Harvey-White J; Cunningham J; Bankiewicz KS
Mol Ther; 2001 Oct; 4(4):324-30. PubMed ID: 11592835
[TBL] [Abstract][Full Text] [Related]
10. Persistent Expression of Dopamine-Synthesizing Enzymes 15 Years After Gene Transfer in a Primate Model of Parkinson's Disease.
Sehara Y; Fujimoto KI; Ikeguchi K; Katakai Y; Ono F; Takino N; Ito M; Ozawa K; Muramatsu SI
Hum Gene Ther Clin Dev; 2017 Jun; 28(2):74-79. PubMed ID: 28279081
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.
San Sebastian W; Richardson RM; Kells AP; Lamarre C; Bringas J; Pivirotto P; Salegio EA; Dearmond SJ; Forsayeth J; Bankiewicz KS
Hum Gene Ther; 2012 Feb; 23(2):210-7. PubMed ID: 22017504
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus-mediated gene transfer of human aromatic L-amino acid decarboxylase protects mixed striatal primary cultures from L-DOPA toxicity.
Doroudchi MM; Liauw J; Heaton K; Zhen Z; Forsayeth JR
J Neurochem; 2005 May; 93(3):634-40. PubMed ID: 15836622
[TBL] [Abstract][Full Text] [Related]
13. Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Riverol M; Ordóñez C; Collantes M; DiCaudo C; Peñuelas I; Arbizu J; Marcilla I; Luquin MR
Neurobiol Dis; 2014 Feb; 62():250-9. PubMed ID: 24076099
[TBL] [Abstract][Full Text] [Related]
14. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.
Bankiewicz KS; Daadi M; Pivirotto P; Bringas J; Sanftner L; Cunningham J; Forsayeth JR; Eberling JL
Exp Neurol; 2006 Feb; 197(2):363-72. PubMed ID: 16337943
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
Cunningham J; Pivirotto P; Bringas J; Suzuki B; Vijay S; Sanftner L; Kitamura M; Chan C; Bankiewicz KS
Mol Ther; 2008 Jul; 16(7):1267-75. PubMed ID: 18523450
[TBL] [Abstract][Full Text] [Related]
16. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors.
Fan DS; Ogawa M; Fujimoto KI; Ikeguchi K; Ogasawara Y; Urabe M; Nishizawa M; Nakano I; Yoshida M; Nagatsu I; Ichinose H; Nagatsu T; Kurtzman GJ; Ozawa K
Hum Gene Ther; 1998 Nov; 9(17):2527-35. PubMed ID: 9853519
[TBL] [Abstract][Full Text] [Related]
17. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain.
Fiandaca MS; Varenika V; Eberling J; McKnight T; Bringas J; Pivirotto P; Beyer J; Hadaczek P; Bowers W; Park J; Federoff H; Forsayeth J; Bankiewicz KS
Neuroimage; 2009 Aug; 47 Suppl 2(Suppl 2):T27-35. PubMed ID: 19095069
[TBL] [Abstract][Full Text] [Related]
18. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
[TBL] [Abstract][Full Text] [Related]
19. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain.
Hadaczek P; Kohutnicka M; Krauze MT; Bringas J; Pivirotto P; Cunningham J; Bankiewicz K
Hum Gene Ther; 2006 Mar; 17(3):291-302. PubMed ID: 16544978
[TBL] [Abstract][Full Text] [Related]
20. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.
Eberling JL; Jagust WJ; Christine CW; Starr P; Larson P; Bankiewicz KS; Aminoff MJ
Neurology; 2008 May; 70(21):1980-3. PubMed ID: 18401019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
